Zolgensma denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for zolgensma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny Zolgensma as Experimental

Despite FDA approval, UnitedHealthcare may classify Zolgensma (onasemnogene abeparvovec) as "experimental" or "investigational" in specific contexts — most commonly when a patient falls outside the population described in the insurer's coverage policy, or when the policy has not been updated to reflect evolving evidence. Gene therapy remains a newer treatment category, and some payers apply heightened scrutiny to it.

This denial is legally and medically challengeable. Zolgensma has received FDA approval for SMA, and federal law distinguishes between treatments that are FDA-approved and those that are genuinely investigational. An insurer may not arbitrarily label an FDA-approved treatment "experimental" without applying a defined, evidence-based review process. Your appeal should directly rebut the experimental classification by documenting FDA approval status and citing the relevant clinical guidelines from recognized professional organizations.

## Your Appeal Rights

• Internal appeal: File within the deadline stated on your denial letter. Under ERISA §503, employer plan members are entitled to a full-and-fair review with access to all materials the plan relied upon.
• External review (ACA §2719): After exhausting internal appeals, request independent external review. The standard window is up to four months from the final adverse decision. For life-threatening or urgent situations, an expedited external review must be completed within 72 hours of the request.
• State insurance department: If your plan is a fully-insured state-regulated plan (not self-funded ERISA), your state insurance commissioner can accept complaints about wrongful experimental denials.

## Documentation to Gather

1. FDA approval documentation — print the current FDA label and approval letter from the FDA website; submit with your appeal as exhibit A. 2. Diagnosis confirmation — genetic testing confirming SMA diagnosis with copy number analysis. 3. Clinical severity and progression notes — functional assessments, pulmonary evaluations, and motor milestone records from the chart. 4. Prescriber letter — your neurologist should explicitly state that Zolgensma is FDA-approved, not investigational, and that it meets the applicable standard of care per recognized SMA guidelines. 5. Relevant guideline citations — reference guidance from the applicable professional society (e.g., Child Neurology Society, SMA expert panel recommendations) without reproducing proprietary numbers.

## Criteria-Mapping Structure

Obtain UnitedHealthcare's current Zolgensma coverage policy (available on UHC's provider and member portals). Compare each stated criterion against the chart:

| Policy / Label Criterion | Supporting Chart or Document | |---|---| | FDA-approval status confirmed | FDA label + approval letter | | Confirmed SMA genetic diagnosis | Genetic report with date | | Patient age / disease stage per label | Chart entry with date | | Treating physician specialty attestation | Neurologist letter |

Your written appeal should open by citing the FDA approval date and approval basis, then walk through each criterion the insurer listed. Reframing the denial from "experimental" to "coverage dispute" — and showing the insurer's own policy language does not support the experimental label — is often the strongest approach in external review.